ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

IMNN Imunon Inc

1.5055
0.0655 (4.55%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Imunon Inc IMNN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.0655 4.55% 1.5055 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.45 1.3801 1.4754 1.44 1.44
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
18/4/202407:30GLOBEIMUNON’s IND Application Cleared to Begin Human Testing of..
11/4/202407:00GLOBEIMUNON Reports Compliance with Nasdaq Listing Requirements
28/3/202407:00GLOBEIMUNON Reports 2023 Financial Results and Provides Business..
25/3/202407:30GLOBEIMUNON Receives $1.3 Million from Sale of its New Jersey Net..
21/3/202416:00GLOBEIMUNON to Hold 2023 Financial Results and Business Update..
13/3/202407:00GLOBEIMUNON Files IND Application to Begin Human Testing of..
12/3/202416:00GLOBEIMUNON Announces Leadership Change
29/2/202407:30GLOBEIndependent Lab Confirms Immunogenicity and Protection with..
27/2/202407:30GLOBEMemorial Sloan Kettering Cancer Center Now Enrolling..
22/2/202407:00GLOBEIMNN-101 Preclinical Data in SARS CoV-2 Published in..
09/2/202415:09EDGAR2Form S-1/A - General form for registration of securities..
29/12/202315:30EDGAR2Form 8-K - Current report
20/12/202316:15EDGAR2Form S-1 - General form for registration of securities under..
11/12/202315:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202315:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
11/12/202307:35EDGAR2Form 8-K - Current report
11/12/202307:30GLOBEIMUNON Appoints Dr. Sebastien Hazard as Chief Medical..
14/11/202308:00GLOBEIMUNON’s VP of R&D to Present at the Vaccines Summit-2023
14/11/202307:00GLOBEIMUNON Reports Third Quarter 2023 Financial Results and..
07/11/202307:30GLOBEIMUNON to Hold Third Quarter 2023 Financial Results and..
23/10/202307:30GLOBEIMUNON’s Chief Science Officer to Present at the 3rd..
19/10/202307:30GLOBEIMUNON CEO Dr. Corinne Le Goff to Participate in a Panel..
18/10/202307:30GLOBEIMUNON Announces First Patient enrolled in Phase 1/2..
06/10/202307:30GLOBEIMUNON Appoints Dr. Patrick Ott to its Scientific Advisory..
28/9/202307:30GLOBEIMUNON Reports Interim Progression-Free Survival and Overall..
26/9/202307:30GLOBEIMUNON Releases Enterprise Video Highlighting the Company’s..
13/9/202307:30GLOBEIMUNON Reminds Investors of its Virtual R&D Day Tomorrow at..
07/9/202315:30GLOBEIMUNON to Host Virtual R&D Day on September 14th Beginning..
05/9/202307:30GLOBEIMUNON to Participate in the H.C. Wainwright Global..
24/8/202315:05GLOBEIMUNON Enters into CRADA for Preclinical Studies of PlaCCine..
14/8/202307:30GLOBEIMUNON Expands Scientific Advisory Board with the Addition..
10/8/202307:00GLOBEIMUNON Reports Second Quarter 2023 Financial Results and..
07/8/202307:30GLOBEPreclinical Data Showing Strong Immunogenicity and..
03/8/202307:30GLOBEIMUNON to Hold Second Quarter 2023 Financial Results and..
27/6/202311:00GLOBEIMUNON Unveils New Manufacturing Capabilities at..
26/6/202316:00GLOBEImunon Reports Inducement Grants under NASDQ Listing Rule..
12/6/202307:30GLOBEIMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy..
08/6/202307:30GLOBEIMUNON’s CEO Presents Business Overview to Investors and..
30/5/202307:00GLOBEIMUNON Presents PlaCCine Preclinical Data at the 2023..
11/5/202307:00GLOBEIMUNON Reports First Quarter 2023 Financial Results and..
04/5/202307:30GLOBEIMUNON to Hold First Quarter 2023 Financial Results and..

Su Consulta Reciente

Delayed Upgrade Clock